NANOPARTICLES (SPFT)

1. Presented By- Chetan Vishwanath Pawar
M. Pharmacy Sem – II
Guided By- Mrs. S. MUTHA
Department of Pharmaceutics
PDEA’s S.G.R.S. College of Pharmacy Saswad.
1

2.  INTRODUCTION
 CLASSIFICATION OF NANOPARTICLES
 ADVANTAGES AND DISADVANTAGEF
 IDEAL CHARACTERISTICS
 METHOD OF PREPARATION
 EVALUATION PARAMETER OF NANOPARTICLES
 APPLICATION OF NANOPARTICLES :
 REFERENCES

3.  DEFINATION –
Nanoparticles are defined as particulate
dispersions or solid particles with a size in the
range of 10-1000nm.
OR
Nanoparticles are sub-nanosized colloidal
structures composed of synthetic or semi-
synthetic polymers.”

4.  Based On Method Of Preparation:
Nanocapsules:-
drug is confined to a cavity surrounded by
a unique polymer membrane.
Nanospheres:-
the drug is physically and uniformly dispersed.

6.  Solid Lipid Nanoparticles
 Polymeric Nanoparticles
 Ceramic Nanoparticles
 Hydrogel Nanoparticles
 Copolymerized Peptide Nanoparticles
 Nanocrystals and Nanosuspensions

7.  Solid Lipid Nanoparticles:
• New type of colloidal drug carrier system for i.v.
• Consists of spherical solid lipid particles in the
nm range, dispersed in water or in aqueous
surfactant solution.
 Polymeric nanoparticles (PNPs) - are defined as
particulate dispersions or solid particles with size
in the range of 10-1000nm.
• Biodegradable polymeric nanoparticles
Polylactic acid (PLA), polyglycolic acid (PGA),
Polylactic - glycolic acid (PLGA)

8.  Ceramic Nanoparticles:
These are the nanoparticles made up of
inorganic(ceramic) compounds silica, Exist in
size less than 50 nm, which helps them in
evading deeper parts of the body.
 Hydrogel nanoparticles:
Polymeric system involving the self-
assembly and self aggregation of natural
polymer cholesterol dextran and agarose
cholesterol groups provide cross linking
points.

9.  Copolymerized Peptide Nanoparticles:
Drug moiety is covalently bound to the
carrier instead of being physically entrapped.
 Nanocrystals And Nanosuspensions:
Pure drug coated with surfactant,
Aggregation of these particles in crystalline
form .Drug powder dispersed in aqueous
surfactant solution.

10.  1) They are suitable for different routes of
administration.
 2) Carrying capacity of nanoparticles is high.
 3) Shelf-stability of drug increases.
 4) Ability to sustain and control drug release
patterns.
 5) Suitable for combination therapy where two or
more drug can be co-delivered.

11.  1) High cost
 2)Productivity more difficult
 3) Reduced ability to adjust the dose
 4) Highly sophisticated technology
 5) Requires skills to manufacture

12.  It should be biochemical inert , non toxic .
 It should be stable both physically and
chemically in In vivo & in vitro conditions.
 Specific Therapeutic amount of drug release
must be possessed .
 The preparation of the delivery system should
be easy.

13.  Emulsion-Solvent Evaporation Method:
 Double Emulsion and Evaporation Method:
 Salting Out Method:
 Emulsions- Diffusion Method
 Solvent Displacement / Precipitation method:

19.  1. Particle size
 2. Density
 3. Molecular weight
 4. Structure and crystallinity
 5. Specific surface area
 6. Surface charge & electronic mobility
 7. Surface hydrophobicity
 8. In vitro release

20.  Targeting drug delivery by encapsulation .
 Nanoparticles for drug delivery into the brain.
 Nanoparticle for ophthalmic delivery.
 Topical formulation.
 Nanoparticles for oral delivery of peptides &
portions .

22.  JAPS Nanoparticle: An overview of preparation
and Characterization BY Sovan Lal Pal, Utpal
Jana, P. K. Manna, G. P. Mohanta, R.
Manavalan
 Pelagia Research Library Formulation,
Characterization and Application on
Nanoparticle: A Review Abhishek Garg*,
Sharad Visht, Nitin Kumar
 Tropical Journal of Pharmaceutical Research,
June 2006; 5 (1): 561-573Nanoparticles – A
Review VJ Mohanraj* and Y Chen